Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769332 | 0.97 | HDAC4 (0.44) | HDAC4HDAC6TP53POLBALOX5 | |
| SCHEMBL5168391 | 0.91 | POLB (0.40) | HDAC4HDAC6TP53POLBTDP1 | |
| SCHEMBL5166925 | 0.90 | S1PR1 (0.43) | POLBTDP1HPGDS1PR4S1PR1 | |
| SCHEMBL5167475 | 0.88 | MAPT (0.40) | HDAC4HDAC6TP53POLBTDP1 | |
| SCHEMBL5167470 | 0.88 | POLB (0.43) | POLBTDP1HPGDS1PR4S1PR1 | |
| SCHEMBL5169197 | 0.88 | POLB (0.45) | POLBTDP1HPGDFAAHS1PR4 | |
| SCHEMBL5168050 | 0.88 | HDAC1 (0.47) | HDAC6FAAH | |
| SCHEMBL386392 | 0.87 | S1PR1 (0.49) | HDAC4HDAC6TP53POLBTDP1 | |
| SCHEMBL5168929 | 0.87 | POLB (0.42) | HDAC4HDAC6POLBTDP1HPGD | |
| SCHEMBL6774680 | 0.87 | POLB (0.44) | POLBTDP1HPGDS1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1300405-B1 | AMINO ALCOHOL DERIVATIVES | SANKYO CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6964976-B2 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2005-11-15 | — | — | US | disclosed |
| US-20040132784-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| US-6723745-B2 | PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | HDAC4 2271/4885HDAC6 3933/4885TP53 3586/4885 |
| US-20040132784-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | HDAC4 2271/4885HDAC6 3933/4885TP53 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.